机构名称：
¥ 2.0
我们还拥有ADC候选2870，现在称为SAC-TMT。和在围手术期的环境中，某些患者即使受益于KeyTruda，他们仍然处于重复的高风险。These patients can potentially benefit from more intensive therapy while avoiding the level of treatment intensity for those patients who don't need it.因此，如果您查看Keynote-671示例，我们的患者已经实现了病理完全反应，而那些没有。And so the idea here with MK-2870 is those patients who have not achieved pathologic complete response and have very high event rates, even with KEYTRUDA, which improves outcomes quite a bit in this population, now, we can add 2870 and hopefully improve their outcomes for there.
MRK.N-默克公司Inc. Investor活动在ASCO
主要关键词
相关文件推荐
